The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway
Abstract
The invasion of malignant glioma cells into the surrounding normal brain tissues is crucial for causing the poor outcome of this tumor type. Recent studies suggest that glioma stem-like cells (GSLCs) mediate tumor invasion. However, it is not clear whether microenvironment factors, such as tumor-associated microglia/macrophages (TAM/Ms), also play important roles in promoting GSLC invasion. In this study, we found that in primary human gliomas and orthotopical transplanted syngeneic glioma, the number of TAM/Ms at the invasive front was correlated with the presence of CD133+ GSLCs, and these TAM/Ms produced high levels of TGF-β1. CD133+ GSLCs isolated from murine transplanted gliomas exhibited higher invasive potential after being cocultured with TAM/Ms, and the invasiveness was inhibited by neutralization of TGF-β1. We also found that human glioma-derived CD133+ GSLCs became more invasive upon treatment with TGF-β1. In addition, compared with CD133− committed tumor cells, CD133+ GSLCs expressed higher levels of type II TGF-β receptor (TGFBR2) mRNA and protein, and downregulation of TGFBR2 with short hairpin RNA inhibited the invasiveness of GSLCs. Mechanism studies revealed that TGF-β1 released by TAM/Ms promoted the expression of MMP-9 by GSLCs, and TGFBR2 knockdown reduced the invasiveness of these cells in vivo. These results demonstrate that TAM/Ms enhance the invasiveness of CD133+ GSLCs via the release of TGF-β1, which increases the production of MMP-9 by GSLCs. Therefore, the TGF-β1 signaling pathway is a potential therapeutic target for limiting the invasiveness of GSLCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Non-Smad pathways in TGF-β signaling
Zhang, Y. E. (2009) · Cell Research · doi:10.1038/cr.2008.328 · Cited by 1,749
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Cited by
Macrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Self-citationThe role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Self-citationTumor associated macrophages and neutrophils in cancer
Galdiero, M. R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., & Jaillon, S. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.003 · Cited by 597
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Glioblastoma: defining tumor niches
Hambardzumyan, D., & Bergers, G. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.009 · Cited by 522
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Overcoming therapeutic resistance in glioblastoma: the way forward
Osuka, S., & Van Meir, E. G. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 511
Fan, Q.-M., Jing, Y.-Y., Yu, G.-F., Kou, X.-R., Ye, F., Gao, L., Li, R., Zhao, Q.-D., Yang, Y., Lu, Z.-H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.008 · Cited by 458
Szulzewsky, F., Pelz, A., Feng, X., Synowitz, M., Markovic, D., Langmann, T., Holtman, I. R., Wang, X., Eggen, B. J. L., Boddeke, H. W. G. M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116644 · Cited by 406
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells
Schonberg, D. L., Miller, T. E., Wu, Q., Flavahan, W. A., Das, N. K., Hale, J. S., Hubert, C. G., Mack, S. C., Jarrar, A. M., Karl, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.002 · Cited by 349
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Shi, Y., Ping, Y.-F., Zhou, W., He, Z.-C., Chen, C., Bian, B.-S.-J., Zhang, L., Chen, L., Lan, X., Zhang, X.-C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15080 · Cited by 344
Self-citationT Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Epithelial-mesenchymal transition in glioblastoma progression
IWADATE, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4113 · Cited by 288
DawnRank: discovering personalized driver genes in cancer
Hou, J. P., & Ma, J. (2014) · Genome Medicine · doi:10.1186/preaccept-1835019729127471 · Cited by 273
Sørensen, M. D., Dahlrot, R. H., Boldt, H. B., Hansen, S., & Kristensen, B. W. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12428 · Cited by 273
Tumor Cell Invasion in Glioblastoma
Vollmann-Zwerenz, A., Leidgens, V., Feliciello, G., Klein, C. A., & Hau, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061932 · Cited by 257
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207
Xue, N., Zhou, Q., Ji, M., Jin, J., Lai, F., Chen, J., Zhang, M., Jia, J., Yang, H., Zhang, J., et al. (2017) · Scientific Reports · doi:10.1038/srep39011 · Cited by 181
Solinas, M., Massi, P., Cinquina, V., Valenti, M., Bolognini, D., Gariboldi, M., Monti, E., Rubino, T., & Parolaro, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076918 · Cited by 159
Li, R., Hebert, J. D., Lee, T. A., Xing, H., Boussommier-Calleja, A., Hynes, R. O., Lauffenburger, D. A., & Kamm, R. D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0442 · Cited by 100
Zhang, Z., Xu, J., Chen, Z., Wang, H., Xue, H., Yang, C., Guo, Q., Qi, Y., Guo, X., Qian, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0759 · Cited by 93
“TAMs promote glioma progression and are regarded as critical cellular components in the glioma microenvironment (8).”
BackgroundGlioblastoma Microenvironment and Cellular Interactions
Crivii, C.-B., Boșca, A. B., Melincovici, C. S., Constantin, A.-M., Mărginean, M., Dronca, E., Suflețel, R., Gonciar, D., Bungărdean, M., & Șovrea, A. (2022) · Cancers · doi:10.3390/cancers14041092 · Cited by 81
Ning, Y., Cui, Y., Li, X., Cao, X., Chen, A., Xu, C., Cao, J., & Luo, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.022 · Cited by 75
Self-citationPharmacological targeting of the tumor–immune symbiosis in glioblastoma
Pang, L., Khan, F., Dunterman, M., & Chen, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.002 · Cited by 36
Metadata
- Authors
- Ye, X.-Z., Xu, S.-L., Xin, Y.-H., Yu, S.-C., Ping, Y.-F., Chen, L., Xiao, H.-L., Wang, B., Yi, L., Wang, Q.-L., Jiang, X.-F., Yang, L., Zhang, P., Qian, C., Cui, Y.-H., Zhang, X., & Bian, X.-W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-01
- Volume
- 189
- Issue
- 1
- Pages
- 444-453
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1934903822
- Cited by
- 477
- References
- 51
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.